Januskinaseinhibitoren zur Therapie der atopischen Dermatitis

Traidl, Stephan; Freimooser, Sina; Werfel, Thomas

doi:10.5414/alx02272

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Efficacy of tofacitinib was demonstrated in psoriasis in phase III and long-term extension trials [ 60 , 61 ]. JAK-1/3 inhibition leads to inhibition of Th1-, Th2-, and Th17-associated cytokines [ 62 , 63 ], which seem to play a role in the pathogenesis of HE [ 1 ]. However, systemic tofacitinib may elevate the risk of deep vein thrombosis and pulmonary embolisms, particularly in patients already at a high risk [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

Transcriptomics- and Genomics-Guided Drug Repurposing for the Treatment of Vesicular Hand Eczema

Rosenberg,

Kamali,

Voorberg

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Vesicular hand eczema (VHE), a clinical subtype of hand eczema (HE), showed limited responsiveness to alitretinoin, the only approved systemic treatment for severe chronic HE. This emphasizes the need for alternative treatment approaches. Therefore, our study aimed to identify drug repurposing opportunities for VHE using transcriptomics and genomics data. We constructed a gene network by combining 52 differentially expressed genes (DEGs) from a VHE transcriptomics study with 3 quantitative trait locus (QTL) genes associated with HE. Through network analysis, clustering, and functional enrichment analyses, we investigated the underlying biological mechanisms of this network. Next, we leveraged drug–gene interactions and retrieved pharmaco-transcriptomics data from the DrugBank database to identify drug repurposing opportunities for (V)HE. We developed a drug ranking system, primarily based on efficacy, safety, and practical and pricing factors, to select the most promising drug repurposing candidates. Our results revealed that the (V)HE network comprised 78 genes that yielded several biological pathways underlying the disease. The drug–gene interaction search together with pharmaco-transcriptomics lookups revealed 123 unique drug repurposing opportunities. Based on our drug ranking system, our study identified the most promising drug repurposing opportunities (e.g., vitamin D analogues, retinoids, and immunomodulating drugs) that might be effective in treating (V)HE.

show abstract